肿瘤微环境
癌症研究
CCL22型
趋化因子
免疫疗法
免疫抑制
SOCS3
免疫学
生物
肿瘤进展
癌症
信号转导
免疫系统
车站3
CXCL10型
细胞生物学
遗传学
作者
Shukai Yuan,Tong Zhu,Jianan Wang,Ruoyu Jiang,Aofeng Shu,Zhenlei Zhang,Peitao Zhang,Xuequan Feng,Li Zhao
出处
期刊:Carcinogenesis
[Oxford University Press]
日期:2023-07-01
卷期号:44 (7): 549-561
被引量:1
标识
DOI:10.1093/carcin/bgad055
摘要
Abstract Immunotherapy is the only approved systemic therapy for advanced cutaneous squamous cell carcinoma (cSCC), however, roughly 50% of patients do not respond to the therapy and resistance often occurs over time to those who initially respond. Immunosuppression could have a critical role in developing treatment resistance, thus, understanding the mechanisms of how immunosuppression is developed and regulated may be the key to improving clinical diagnosis and treatment strategies for cSCC. Here, through using a series of immunocompetent genetically engineered mouse models, we demonstrate that miR-22 promotes cSCC development by establishing regulatory T cells (Tregs)-mediated immunosuppressive tumor microenvironment (TME) in a tumor cell autonomous manner. Mechanism investigation revealed that miR-22 elicits the constitutive activation of JAK/STAT3 signaling by directly targeting its suppressor SOCS3, which augments cancer cell-derived chemokine secretion and Tregs recruitment. Epithelial-specific and global knockouts of miR-22 repress papilloma and cSCC development and progression, manifested with reduced Tregs infiltration and elevated CD8+ T cell activation. Transcriptomic analysis and functional rescue study confirmed CCL17, CCL20 and CCL22 as the main affected chemokines that mediate the chemotaxis between miR-22 highly expressing keratinocyte tumor cells and Tregs. Conversely, overexpression of SOCS3 reversed miR-22-induced Tregs recruitment toward tumor cells. Clinically, gradually increasing Tregs infiltration during cSCC progression was negatively correlated with SOCS3 abundance, supported by previously documented elevated miR-22 levels. Thus, our study uncovers a novel miR-22–SOCS3–JAK/STAT3–chemokines regulatory mechanism in defining the immunosuppressive TME and highlights the promising clinical application value of miR-22 as a common targeting molecule against JAK/STAT3 signaling and immune escape in cSCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI